Quota Virtual Diversion Awareness Training

DAYS: April 2, 7,8,9,16, 2026 | 1:00 p.m. to 2:00 p.m. EST | ZOOM - Webinar Platform

The Diversion Control Division (DCD) of the Drug Enforcement Administration (DEA) is pleased to present a series of five (5) webinars covering supply chain matters relating to quota. This training primarily focuses on manufacturers, distributors, and importers of schedule I and II controlled substances and certain list I chemicals (ephedrine, pseudoephedrine, and phenylpropanolamine). You may register for any or all of the following webinars of interest to you or your business.

There is no registration fee for these events. Capacity is limited to the first 3,000 attendees.

---

Thursday, April 2: International Treaties/Controlled Substances Act

Summary: Discussion regarding the relationship between the 1961 Single Convention, 1971 Psychotropic Convention, 1988 Precursor Chemical Convention and the Controlled Substances Act (CSA); DEA's responsibilities regarding quota management under the three drug control treaties and the CSA; and how DEA communicates with the public regarding the three drug control treaties and the CSA.

Speaker: Sandy G. Ghozland, Drug Science Specialist, UN Reporting and Quota

Important Notice: This webinar is a two-part registration process. Please complete both steps to confirm your attendance.

Register Now for the Virtual Webinar

Confirmation of registration will be sent to each attendee's email address.

Any questions regarding this conference may be directed to: VDAT@dea.gov

---

Tuesday, April 7: Aggregate Production Quota (APQ) and Assessment of Annual Needs (ANN) for List for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine

Summary: Discussion regarding drug control under the Controlled Substances Act (CSA), description and purpose of the Aggregate Production Quota (APQ) and Assessment of Annual Needs (AAN), the factors DEA considers when building the APQ and AAN and their relationship to the allotment of individual manufacturing, procurement, and importation quotas, as well as the factors DEA considers in adjudicating individual manufacturing, procurement, and importation quotas.

Speaker: Paul S. Loor, Drug Science Specialist, UN Reporting and Quota

Important Notice: This webinar is a two-part registration process. Please complete both steps to confirm your attendance.

Register Now for the Virtual Webinar

Confirmation of registration will be sent to each attendee's email address.

Any questions regarding this conference may be directed to: VDAT@dea.gov

---

Wednesday, April 8: Quota Management System (QMS) Online

Summary: Discussion on why the Quota Management System (QMS) was developed; the user interface display and specific considerations regarding manufacturing, procurement, or import quotas requests; and guidance to registrants regarding the submission of data necessary to adjudicate individual quota applications.

Speaker: Miessa Brown, Drug Science Specialist, UN Reporting and Quota

Important Notice: This webinar is a two-part registration process. Please complete both steps to confirm your attendance.

Register Now for the Virtual Webinar

Confirmation of registration will be sent to each attendee's email address.

Any questions regarding this conference may be directed to: VDAT@dea.gov

---

Thursday, April 9: Year End Reports System (YERS) Online

Summary: Discussion on why the Year-End Reporting System (YERS) was developed; specific user interface displays for manufacturing, procurement, or import data submission; how the data will be utilized to demonstrate U.S. compliance with the three UN drug control treaties and domestic adherence to the CSA and its conforming regulations.

Speaker: Karon A. Hall, Drug Science Specialist, UN Reporting and Quota

Important Notice: This webinar is a two-part registration process. Please complete both steps to confirm your attendance.

Register Now for the Virtual Webinar

Confirmation of registration will be sent to each attendee's email address.

Any questions regarding this conference may be directed to: VDAT@dea.gov

---

Thursday, April 16: Research vs Manufacturing

Summary: Discussion regarding the difference between research and manufacturing of controlled substances under the Controlled Substances Act (CSA) and its implementing regulations; and clarification of what coincidental activities may occur under each DEA registration.

Speaker: Gregory J. Kavanagh, Drug Science Specialist, UN Reporting and Quota

Important Notice: This webinar is a two-part registration process. Please complete both steps to confirm your attendance.

Register Now for the Virtual Webinar

Confirmation of registration will be sent to each attendee's email address.

Any questions regarding this conference may be directed to: VDAT@dea.gov

DEA Washington Division -
Opioid Treatment Program (OTP) Healthcare Summit

Wednesday, April 15, 2026 | 9:00 AM – 12:00 PM (EST) | In-person and Virtual

The Drug Enforcement Administration - Washington Division’s Baltimore District Office will be hosting the Opioid Treatment Program (OTP) Healthcare Summit to present an overview of Controlled Substances (CS) regulations and the DEA Registrant responsibilities under the Controlled Substances Act (CSA) to ensure the proper handling of controlled prescription drugs, and the identification and prevention of diversion activity stemming from various sources. The summit brings together clinical, compliance, and public Safety leaders to strengthen Opioid Treatment delivery through regulatory clarity, operational excellence, and collaborative solutions.

Audience:

• The Summit will welcome participants from Maryland: Howard County, Baltimore County, Baltimore City, Anne Arundel County, and neighboring areas.
• Essential for professionals responsible for OTP oversight, diversion prevention, patient safety, and program Integrity. Registered DEA Narcotic Treatment Programs (including Maintenance, Detoxification, Maintenance/Detoxification, Compounder/Maintenance, Compounder/Detoxification, Compounder/Maintenance/Detoxification)
• DEA Registrants, healthcare professionals and support staff

Moderator:
Justin G. Wood - Diversion Program Manager, DEA Washington Division

Location:

James N. Robey Public Safety Training Center
2200 Scott Wheeler Dr, Marriottsville, MD 21104

WebEx Webinar Platform - Simultaneous broadcast

Virtual Registration: WebEx Webinars
(capacity is limited to the first 500 attendees)

For In-person Registration, please download and complete the PDF form and email the document to: WashingtonDiversionOutreach@dea.com
A confirmation email will be sent once your registration is successful.

In-Person Registration Form (PDF)
(capacity is limited to the first 100 attendees)

Registration is required. There is no registration fee. This is a LIVE event and not recorded. The program is informational and not for credit.

The contents of the presentations, to include speaker remarks, do not have the force and effect of law and are not meant to bind the public in any way. It is intended only for educational purposes to provide clarity to the public regarding existing resources or requirements under the law or agency policies. The statements contained during the summit that are not embodied in the law are not binding on DEA.

Any questions may be directed to Lillianect Rivas-Mattei, Diversion Program Specialist (Outreach Coordinator) via email to: WashingtonDiversionOutreach@dea.gov